Molecular Instruments and Visiopharm Announce Strategic Partnership to Combine AI-Driven Precision Pathology with HCR™ Pro Assays to Advance Clinical-Grade RNA-ISH


Molecular Instruments and Visiopharm Announce Strategic Partnership to Combine AI-Driven Precision Pathology with HCR™ Pro Assays to Advance Clinical-Grade RNA-ISH

LOS ANGELES, Nov. 6, 2024 /PRNewswire/ -- Molecular Instruments® (MI), the inventor of the HCR™ Imaging technology, is pleased to announce a strategic partnership with Visiopharm, a global leader in AI-driven precision pathology software. This collaboration brings together MI's clinical-grade HCR™ platform with Visiopharm's Oncotopix® Discovery software, empowering users with a highly flexible, deep learning approach to precise and efficient image analysis for RNA-ISH assays.

We want to hear from you For general questions or concerns, email web@abqjournal.com

Previous articleNext article

POPULAR CATEGORY

corporate

10263

tech

11464

entertainment

12622

research

5711

misc

13376

wellness

10176

athletics

13345